Protection conferred by the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine to patients hospitalized with COVID-19 in Greece in 2023–2024 - 11/12/25
, Vasiliki Rapti b, 1, Vasileios Petrakis c, 1, Maria N. Gamaletsou d, 1, Evangelia Voulgaraki b, 1, Theodoros V. Giannouchos e, 1, Eirini Antoniadou f, 1, Konstantinos Kounouklas g, 1, Dimitrios Basoulis d, Αmalia Karapanou h, Eleni Karantoni g, Maria Chini f, Garyfalia Poulakou b, Periklis Panagopoulos c, Dimitrios Hatzigeorgiou i, Konstantinos N. Syrigos b, Nikolaos V. Sipsas d
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Aim |
To estimate the protection that the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine conferred to COVID-19 patients hospitalized in Greece during the 2023–2024 season.
Methods |
Data were collected from five tertiary-care hospitals from November 2023 through May 2024. Multivariable logistic and Poisson regression models were used to estimate the association between COVID-19 vaccination status, adverse outcome [intensive care unit (ICU) admission, invasive mechanical ventilation, death], and in-hospital length-of-stay.
Results |
All in all, 579 patients with COVID-19 [mean age: 76.7 years; 547 (94.5 %) patients with ≥ 1 comorbidity] were hospitalized for a mean 7.2 days during the study period. Overall, 111 (19.2 %) were unvaccinated, 437 (75.5 %) had been vaccinated against COVID-19 in the past, and 31 (5.3 %) had received the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine. Unvaccinated individuals were disproportionately more likely to be admitted to an ICU (6.3 % versus 1.6 % versus 0.0 %; p-value = 0.01), to be intubated (6.3 % versus 1.8 % versus 0.0 %; p-value = 0.02), and to die (12.6 % versus 8.9 % versus 6.5 %; p-value = 0.42) compared to partially and fully vaccinated individuals. Multivariable analysis found that vaccination with the Omicron XBB.1.5-adapted monovalent mRNA vaccine significantly reduced the odds of in-hospital mortality [adjusted odds ratio: 0.37; 95 % confidence interval (CI): 0.15–0.90] and was associated with shorter in-hospital length-of-stay [incidence rate ratio: 0.71; 95 % CI: 0.50–0.98) compared to no vaccination.
Conclusions |
In comparison with unvaccinated individuals, the Omicron XBB.1.5-adapted monovalent COVID-19 mRNA vaccine conferred significant protection against in-hospital mortality and reduced length of stay to COVID-19 patients hospitalized in Greece during the 2023–2024 season.
Le texte complet de cet article est disponible en PDF.Keywords : XBB.1.5-adapted mRNA vaccine, Hospitalization, Adverse outcomes
Plan
Vol 55 - N° 8
Article 105183- décembre 2025 Retour au numéro
Article précédent
- Efficacy of dolutegravir-based regimen in HIV-infected children in a treatment center in a regional health facility in Cameroon
- Andreas Chiabi, Sankara Nykam, Kate Kan, Cecilia Fomenky, Lucas M. Tanlaka, Franklin N. Ngueiwoh, Christabelle Ewane, Vanessa M. Fozao, Denis Nsame
- Beta-lactam underdosing is not more frequent in COVID-19 than in non-COVID-19 critically ill patients
- Maeva Palayer, Juliette Bernier, Emmanuel Pardo, Franck Verdonk, Tomas Urbina, Emmanuel Bourgogne
Bienvenue sur EM-consulte, la référence des professionnels de santé.